If you are looking for an opportunity to demonstrate national leadership and are seeking ways to impact the care that is delivered to Canadians with cancer, you may be interested in participating in the pan-Canadian Oncology Drug Review (pCODR). pCODR is currently recruiting for membership on the pCODR Expert Review Committee (pERC), due to some upcoming term expirations. We are seeking the following member types, with membership to begin September 2015 for a two or three year term:
- Three (3) Oncologists
- One (1) Health Economist
- One (1) Pharmacist
Also, pCODR continuously recruits oncologists to sit on the 11 clinical guidance panels, which are structured around specific tumour types, e.g. breast, endocrine, gastrointestinal, genitourinary, head and neck, leukemia, lymphoma and myeloma, lung, melanoma, neuro-oncology, sarcoma. We are also in need of economists, with knowledge of pharmaeconomics, to participate on the economic guidance panels.
The nomination package provides a clear outline of the criteria and process to become a pERC member or a member of pCODR’s clinical or economic guidance panels. Nominations/submissions for the pERC member positions will be accepted until 5 p.m. EDT, June 12, 2015. All other applications for clinical or economic panels will be accepted on an on-going basis. If you have any questions, please contact email@example.com
pCODR was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. In April 2014, pCODR was transferred to the Canadian Agency for Drugs and Technologies in Health (CADTH).